Teva Pharmaceutical Industries Limited
TEVA
$36.63
$0.110.29%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.14B | 3.98B | 4.71B | 4.48B | 4.18B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.14B | 3.98B | 4.71B | 4.48B | 4.18B |
| Cost of Revenue | 1.99B | 2.01B | 2.06B | 2.18B | 2.07B |
| Gross Profit | 2.15B | 1.97B | 2.66B | 2.30B | 2.10B |
| SG&A Expenses | 1.03B | 1.00B | 1.12B | 973.00M | 959.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.00M | -14.00M | -17.00M | 9.00M | 5.00M |
| Total Operating Expenses | 3.98B | 3.22B | 3.43B | 3.41B | 3.28B |
| Operating Income | 167.00M | 763.00M | 1.29B | 1.07B | 894.00M |
| Income Before Tax | -455.00M | 436.00M | 90.00M | 648.00M | 204.00M |
| Income Tax Expenses | 121.00M | 67.00M | -390.00M | 214.00M | -78.00M |
| Earnings from Continuing Operations | -576.00M | 369.00M | 480.00M | 434.00M | 282.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | -1.00M | -- |
| Net Income | -576.00M | 369.00M | 480.00M | 433.00M | 282.00M |
| EBIT | 167.00M | 763.00M | 1.29B | 1.07B | 894.00M |
| EBITDA | 408.00M | 1.00B | 1.55B | 1.32B | 1.15B |
| EPS Basic | -0.49 | 0.32 | 0.42 | 0.38 | 0.25 |
| Normalized Basic EPS | -0.03 | 0.30 | 0.58 | 0.45 | 0.35 |
| EPS Diluted | -0.49 | 0.31 | 0.41 | 0.37 | 0.24 |
| Normalized Diluted EPS | -0.03 | 0.29 | 0.57 | 0.45 | 0.35 |
| Average Basic Shares Outstanding | 1.17B | 1.16B | 1.15B | 1.15B | 1.15B |
| Average Diluted Shares Outstanding | 1.17B | 1.18B | 1.17B | 1.16B | 1.16B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |